title: Inhibition of arterial lesion progression in CD16-deficient mice: evidence for altered immunity and the role of IL-10.
abstract: OBJECTIVE
  Given the importance of IgG Fc receptors in immune regulation, we hypothesized that Fcg receptor type III (FcgRIII, CD16) plays an important role in atherogenesis. We therefore analysed the formation of arterial lesions in LDL receptor-deficient (LDLR(-/-)) and FcgRIII(-/-)xLDLR(-/-) double knockout mice at three different points up to 24 weeks of exposure to a high-fat diet.
  
  
  RESULTS
  Analysis of Oil Red-O-stained sections revealed no difference in lesion formation between strains after 6 weeks of a high-fat diet, and a modest decrease after 14 weeks in double knockouts relative to LDLR(-/-) controls. After 24 weeks, lesion formation was decreased in the aortic root (30%) and innominate artery (50%) in FcgRIII double knockouts relative to LDLR(-/-) controls. Analysis of peripheral CD4+ T-cells by intracellular flow cytometry from double knockouts after 24 weeks of a high-fat diet revealed statistically significant increases in the percentages of cells producing interferon-gamma, interleukin (IL)-10, and IL-4 relative to controls, differences that were also observed by analyses of whole aortas for cytokine mRNA levels. As determined by flow cytometry, FcgRIII deficiency resulted in an expansion of CD4+ cells and an increase in the CD4 to CD8 ratio. Analysis of plasma anti-oxidized LDL (OxLDL) antibodies by chemiluminescent assay revealed that IgG1 and IgG2c titers to OxLDL were increased in FcgRIII (-/-)xLDLR(-/-) double knockouts relative to LDLR(-/-) controls, while total IgG levels were similar.
  
  
  CONCLUSIONS
  These results reveal altered immunity in FcgRIII(-/-)xLDLR(-/-) mice and a reduction in lesion formation associated with increased production of IL-10 by an expansion of CD4+ T-cells. The reduction in lesion formation was manifest well after evidence of an immune response to OxLDL, suggesting that FcgRIII contributes to lesion progression in murine atherosclerosis.
authors.affiliation: Veterans Affairs Medical Center, VT 05009, USA.
authors.forename: John A
authors.initials: JA
authors.lastname: Kelly
authors.forename: Mary E
authors.initials: ME
authors.lastname: Griffin
authors.forename: Roy A
authors.initials: RA
authors.lastname: Fava
authors.forename: Sheryl G
authors.initials: SG
authors.lastname: Wood
authors.forename: Katherine A
authors.initials: KA
authors.lastname: Bessette
authors.forename: Elizabeth R
authors.initials: ER
authors.lastname: Miller
authors.forename: Sally A
authors.initials: SA
authors.lastname: Huber
authors.forename: Christoph J
authors.initials: CJ
authors.lastname: Binder
authors.forename: Joseph L
authors.initials: JL
authors.lastname: Witztum
authors.forename: Peter M
authors.initials: PM
authors.lastname: Morganelli
mesh_terms: D000818:Animals; D001158:Arteries / Q000473:pathology*; D050197:Atherosclerosis / Q000473:pathology; D001323:Autoantibodies / Q000097:blood; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D016207:Cytokines / Q000096:biosynthesis; D005260:Female; D007109:Immunity; D007371:Interferon-gamma / Q000502:physiology; D016753:Interleukin-10 / Q000502:physiology*; D008055:Lipids / Q000097:blood; D008077:Lipoproteins, LDL / Q000276:immunology; D008297:Male; D051379:Mice; D017452:Receptors, IgG / Q000502:physiology*; D011973:Receptors, LDL / Q000172:deficiency / Q000502:physiology
chemical_list: D001323:Autoantibodies; D016207:Cytokines; D008055:Lipids; D008077:Lipoproteins, LDL; D017452:Receptors, IgG; D011973:Receptors, LDL; C099252:oxidized low density lipoprotein; D016753:Interleukin-10; D007371:Interferon-gamma